| 2.555 -0.075 (-2.85%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.02  |
1-year : | 4.68 |
| Resists | First : | 3.44 |
Second : | 4.01 |
| Pivot price | 3.22 |
|||
| Supports | First : | 2.52 |
Second : | 2.1 |
| MAs | MA(5) : | 2.73 |
MA(20) : | 3.37 |
| MA(100) : | 3.97 |
MA(250) : | 4.99 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 3.9  |
D(3) : | 3.9 |
| RSI | RSI(14): 17.2 |
|||
| 52-week | High : | 7.82 | Low : | 2.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TARA ] has closed above bottom band by 6.4%. Bollinger Bands are 133.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.67 - 2.69 | 2.69 - 2.71 |
| Low: | 2.48 - 2.51 | 2.51 - 2.53 |
| Close: | 2.52 - 2.57 | 2.57 - 2.6 |
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Mon, 21 Sep 2026
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Mon, 21 Sep 2026
Protara Therapeutics (Nasdaq:TARA) - Stock Analysis - Simply Wall Street
Thu, 13 Aug 2026
Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios - Stock Titan
Tue, 11 Aug 2026
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline - Seeking Alpha
Tue, 21 Jul 2026
Should I buy Protara Therapeutics (TARA) - Zacks Investment Research
Tue, 21 Jul 2026
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 78.3 (%) |
| Shares Short | 4,540 (K) |
| Shares Short P.Month | 4,540 (K) |
| EPS | -1.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -45.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -66 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -1.88 |
| PEG Ratio | 0 |
| Price to Book value | 0.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|